Skip to content

Phase 3 Open label clinical study designed to evaluate the dermatological safety on healthy human subjects.

Evaluation of dermatological safety of investigational Product by 24hrs patch test under complete occlusion on healthy human subjects. - CROM07/2020

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023304
Enrollment
30
Registered
2020-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dermal patch: Dermal Cosmetics patch Patch application on skin Duration- 9 days which include patch removal time Control Intervention1: NA: Single Arm Trial

Sponsors

Almora Botanica
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects in age group 18 - 65 years (both the ages inclusive) 2. Healthy male subjects. 3. Subjects with Fitzpatrick skin type III to V. 4. Subjects willing to give a written informed consent. 5. Subjects willing to maintain the patch test in position for 24 hours. 6. Subject having not participated in a similar investigation in the past one month. 7. Subjects willing to come for regular follow up visits. 8. Subjects ready to follow instructions during the study period.

Exclusion criteria

Exclusion criteria: 1. Infection, allergy on the tested area. 2. Skin allergy, antecedents or atopic subjects. 3. Athletes and subjects with history of excessive sweating. 4. Cutaneous disease which may influence the study result. 5. Subjects on oral corticosteroid. 6. Subjects participating in any other cosmetic or therapeutic study. 7. Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.

Design outcomes

Primary

MeasureTime frame
Safety on dermal patch tests for all the products.Timepoint: 9 days

Secondary

MeasureTime frame
Safety on dermal patch tests for all the products.Timepoint: 9 days

Countries

India

Contacts

Public ContactDr Vijaykumar Shivajirao Patil

CROM Clinical Research and Medical Tourism Pvt. Ltd.

clinicalresearchgoa@gmail.com9158592177

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026